Dickens Caroline, Duarte Raquel, Zietsman Annelle, Cubasch Herbert, Kellett Patricia, Schüz Joachim, Kielkowski Danuta, McCormack Valerie
Section of Environment and Radiation, International Agency for Research on Cancer, Lyon, France. Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2311-21. doi: 10.1158/1055-9965.EPI-14-0603. Epub 2014 Aug 20.
Receptor-defined breast cancer proportions vary across Africa. They have important implications for survival prospects and research priorities.
We studied estrogen receptor (ER), progesterone receptor (PR), and HER2 receptor statuses in two multiracial Southern African countries with routine diagnostic immunohistochemistry. A total of 12,361 women with histologically confirmed breast cancer diagnosed at age ≥20 years during (i) 2009-2011 from South Africa's national cancer registry (public sector) and (ii) 2011-2013 from Namibia's only cancer hospital were included. Crude, age, and age + laboratory-adjusted ORs of receptor status were analyzed using logistic regression, and age-incidence curves were analyzed using Poisson regression.
A total of 10,047 (81%) women had known ER status. Ranking of subtypes was consistent across races: ER(+)/PR(+)HER2(-) was most common (race-specific percentage range, 54.6%-64.8%), followed by triple-negative (17.4%-21.9%), ER(+)/PR(+)HER2(+) (9.6%-13.9%), and ER(-)PR(-)HER2(+) (7.8%-10.9%). Percentages in black versus white women were 33.8% [95% confidence (CI), 32.5-35.0] versus 26.0% (24.0-27.9) ER(-); 20.9% (19.7-22.1) versus 17.5% (15.4-19.6) triple-negative; and 10.7% (9.8-11.6) versus 7.8% (6.3-9.3) ER(-)PR(-)HER2(+). Indian/Asian and mixed-ancestry women had intermediate values. Age-incidence curves had similar shapes across races: rates increased by 12.7% per year (12.2-13.1) across ER subtypes under the age of 50 years, and thereafter slowed for ER(+) (1.95%) and plateaued for ER(-) disease (-0.1%).
ER(+) breast cancer dominates in all Southern African races, but black women have a modest excess of aggressive subtypes.
On the basis of the predominant receptor-defined breast tumors in Southern Africa, improving survival for the growing breast cancer burden should be achievable through earlier diagnosis and appropriate treatment.
受体定义的乳腺癌比例在非洲各地有所不同。它们对生存前景和研究重点具有重要影响。
我们在两个具有多民族人口的南部非洲国家,通过常规诊断免疫组织化学研究了雌激素受体(ER)、孕激素受体(PR)和HER2受体状态。纳入了总共12361名年龄≥20岁且组织学确诊为乳腺癌的女性,她们分别来自:(i)2009 - 2011年南非国家癌症登记处(公共部门);(ii)2011 - 2013年纳米比亚唯一的癌症医院。使用逻辑回归分析受体状态的粗比值比、年龄调整比值比和年龄 + 实验室调整比值比,并使用泊松回归分析年龄发病率曲线。
总共10047名(81%)女性已知ER状态。各亚型的排名在不同种族间一致:ER(+)/PR(+)HER2(-)最常见(种族特异性百分比范围为54.6% - 64.8%),其次是三阴性(17.4% - 21.9%)、ER(+)/PR(+)HER2(+)(9.6% - 13.9%)和ER(-)PR(-)HER2(+)(7.8% - 10.9%)。黑人女性与白人女性中ER(-)的比例分别为33.8% [95%置信区间(CI),32.5 - 35.0] 与26.0%(24.0 - 27.9);三阴性的比例分别为20.9%(19.7 - 22.1)与17.5%(15.4 - 19.6);ER(-)PR(-)HER2(+)的比例分别为10.7%(9.8 - 11.6)与7.8%(6.3 - 9.3)。印度/亚洲和混血女性的比例处于中间值。不同种族的年龄发病率曲线形状相似:在50岁以下,各ER亚型的发病率每年增加12.7%(12.2 - 13.1),此后ER(+)亚型发病率增速放缓至1.95%,ER(-)亚型发病率趋于平稳(-0.1%)。
ER(+)乳腺癌在南部非洲所有种族中占主导,但黑人女性中侵袭性亚型的比例略高。
基于南部非洲以受体定义为主的乳腺肿瘤情况,通过早期诊断和适当治疗,有望提高不断增加的乳腺癌负担人群的生存率。